(A) Anti-MOG antibodies measured ...

Slides:

Advertisements

Similar presentations

(A) Western ... (A) Western blot showing DTX1 knockdown with siRNA in human CD4+ T cells. Actin was used as the loading control. (B) Purified.

Advertisements

Kaplan–Meier analysis for ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Fig. 1. Axial, coronal, and sagittal views of post hoc results (mean gFA) demonstrating significant differences ... Fig. 1. Axial, coronal, and sagittal.

(A) Calcinosis cutis on the extensor side of the left upper arm ...

Figure 1 Mechanism of mortality benefit associated with radial access

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

AHA: American Heart Association; ALT: ...

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Source: Figure created by the author based on data ...

(A) Axial ... (A) Axial images showed symmetric, strong high intensity in the connective tissues surrounded by femoral muscles and mild high intensity.

bDMARD: biologic DMARD.

(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

(A) Pelvic X-ray showing diffuse osteoaddensing ...

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

(A, B) Upon presentation large, scaly, annular plaques with well-defined, erythematous, raised ... (A, B) Upon presentation large, scaly, annular plaques.

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

High IFN-α levels were found in patient’s serum, and ...

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 3 Interrelationship between themes describing the experiences of people with shoulder disorders Unless provided in the caption above, the following.

x-axis, post-partum days. Closed ...

Fig. 1 HRCT of the chest, showing centrilobular nodules (white arrows in A and B), a large subpleural nodule (black ... Fig. 1 HRCT of the chest, showing.

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Papules in an old tattoo as the presenting sign of systemic sarcoidosis in an otherwise asymptomatic ... (A) Nodular papules in the tattoo. (B)

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Rats were treated for 21 days ...

Fig. 1 Flow chart for selection of study subjects

Prevalence and distribution of ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Figure 1 MIC test strips showing reversion of daptomycin resistance of isolate 5 passaged in vitro. This figure ... Figure 1 MIC test strips showing reversion.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Fig. 1 Comparison of LOX concentrations between study groups

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1 A network representation of top 100 co-occurring terms

Fig. 1 Statistics of the main characters’ dialogues.

Figure 1 Patient selection.

Fig. 1 Query formulation process in CLIR

Vestibular lesion of ... Vestibular lesion of the patient before (A) and after (B) prednisone treatment, and histological aspect of the lesion, showing.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of.

(A) Coronal reconstruction CT ...

(A, B) Upon presentation large, scaly, annular plaques with well-defined, erythematous, raised ... (A, B) Upon presentation large, scaly, annular plaques.

(A) Western ... (A) Western blot showing DTX1 knockdown with siRNA in human CD4+ T cells. Actin was used as the loading control. (B) Purified.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Table 2. Mean noise level results for hand dryers in dBA

Presentation transcript:

(A) Anti-MOG antibodies measured ... (A) Anti-MOG antibodies measured by cell-based assay at baseline. The dashed line represents the cut-off. Twelve of one hundred and seventy-four patients (1–12) were MOG-seropositive. (B) Longitudinal serum samples revealed persisting anti-MOG antibodies in six patients and newly occurring in two (13–14). (C) Five out of one hundred and seventy-four patients were neurofascin 186-seropositive at baseline. (D) Longitudinal serum samples revealed persisting anti-neurofascin 186 antibodies in three patients and newly occurring in one (6). (E–G) Brain MRI of a MOG seropositive patient (Patient 1 in Fig. 1A and B, marked with *). (E, F) Coronary T2 fluid-attenuated image (FLAIR); (G) Axial FLAIR. Lesions are marked with red arrows. GMCFI: geometric mean channel fluorescence intensity; MOG: myelin oligodendrocyte glycoprotein. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.comThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Rheumatology (Oxford), Volume 58, Issue 5, 27 September 2018, Pages 908–913, https://doi.org/10.1093/rheumatology/key282 The content of this slide may be subject to copyright: please see the slide notes for details.

This cross-sectional study included 174 patients with SLE ... This cross-sectional study included 174 patients with SLE that were part of the Swiss SLE Cohort Study. Serum samples at study baseline were screened for antibodies against 12 different myelin/neuronal antigens using cell-based assays. Antibodies against myelin oligodendrocyte glycoprotein and neurofascin 186 were additionally measured in longitudinal samples (*) where available (n = 102 patients, n = 182 samples, 1–5 follow-up samples/patient). The last row summarizes the number of patients (absolute and percentage of total cohort) that harbour or develop the various antibodies over the disease course and at baseline (in parentheses). Ig: immunoglobulin. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.comThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Rheumatology (Oxford), Volume 58, Issue 5, 27 September 2018, Pages 908–913, https://doi.org/10.1093/rheumatology/key282 The content of this slide may be subject to copyright: please see the slide notes for details.